View Clinical Trial (Medical Research Study)
Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma
| City: |
|
Sacramento |
| State: |
|
California |
| Zip Code: |
|
95817 |
| Conditions: |
|
Endometrial Carcinoma |
| Purpose: |
|
Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole
blocks estrogen production in the body. The purpose of this study is to determine if the
investigators can predict which patients might benefit from Letrozole treatment by studying
the many different forms of the estrogen receptor molecule that exist within the cancer
tissues. To participate in this study, the patients must be 40 years of age or older and
have biopsy-proven endometrial carcinoma, either well differentiated or moderately
differentiated forms. Also, to be eligible to participate in this study, the patients need
to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will
need a blood test (FSH) to confirm that they have gone into menopause.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium
- Post menopausal status must be demonstrated
- Signed informed consent
Exclusion Criteria:
- FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the
endometrium
- Younger than 40 or postmenopausal status not established
- Pregnant or breastfeeding
|
| NCT ID: |
|
NCT00997373 |
| Primary Contact: |
|
Principal Investigator
Lloyd H. Smith, MD, PhD
University of California, Davis
Lloyd H. Smith, MD, PhD
Phone: 916-734-6945
Email: lhsmith@ucdavis.edu
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Sacramento, California 95817
United States
Lloyd H. Smith, MD, PhD
Phone: 916-734-6930
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 23, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|